Article

The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.

Psychiatry Department, Uludag University Medical Faculty, Bursa, Turkey.
Journal of Psychopharmacology (impact factor: 3.04). 11/2009; 23(8):993-6. DOI:10.1177/0269881108093843 pp.993-6
Source: PubMed

ABSTRACT QTc interval prolongation may appear as a consequence of both typical and atypical antipsychotic treatments. Ziprasidone, which is effective in treating schizophrenia, is associated with QTc prolongation. Although the prolongation of QTc with ziprasidone treatment is often pronounced, there is a scarce number of cases reported about the relationship between ziprasidone and QTc prolongation. Of the three cases presented in this case series, two cases showed values exceeding 0.50 s with ziprasidone treatment.

0 0
 · 
0 Bookmarks
 · 
14 Views
  • Article: Evidence review and clinical guidance for the use of ziprasidone in Canada.
    David Gardner, Andrea Murphy, Stan Kutcher, Serge Beaulieu, Carlo Carandang, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Claire O Donovan, Ayal Schaffer, Jorge Soni, Valerie Taylor, Richard Williams
    [show abstract] [hide abstract]
    ABSTRACT: While indicated for schizophrenia and acute mania, ziprasidone's evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success.
    Annals of General Psychiatry 01/2013; 12(1):1. · 1.56 Impact Factor
  • Source
    Article: Analytic Reviews: Atypical Antipsychotics for the Treatment of ICU Delirium.
    Neil A Gilchrist, Ifeoma Asoh, Bruce Greenberg
    [show abstract] [hide abstract]
    ABSTRACT: Delirium is commonly described in critically ill patients as 1 factor contributing to increased length of intensive care unit and hospital stay, secondary complications, and increased mortality. Initial screening tools for delirium in hospitalized patients are generally easy to use; however, many centers have struggled with implementing these tools in a consistent and systematic manner. Haloperidol has traditionally been prescribed as the primary agent of choice for the treatment of delirium in critically ill patients. Clinicians have been challenged to consider alternative agents due to adverse effects such as extrapyramidal symptoms, QTc prolongation, and possible torsades de pointes with haloperidol use. The atypical antipsychotics are attractive alternatives to haloperidol with improved safety profiles but are flawed by limited data to support dosing and efficacy in this patient population. Future studies that provide large, prospective, double-blinded, placebo-controlled data to support the implementation of these agents as standard therapy over haloperidol are needed.
    Journal of Intensive Care Medicine 03/2011;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

atypical antipsychotic treatments
 
case series
 
cases
 
QTc
 
QTc interval prolongation
 
QTc prolongation
 
scarce number
 
schizophrenia
 
three cases
 
typical
 
ziprasidone
 
ziprasidone treatment
 

S S Eker